ORIC presents Phase 1b data on ORIC-101 in prostate cancer and preclinical data on ORIC-114

Oric Pharmaceuticals, Inc.

ORIC-101 (240 mg) + enzalutamide well tolerated at RP2D; adverse events mostly Grade 1-2, consistent with enzalutamide alone.
No drug-drug interaction; plasma concentrations inhibited GR target; 76% of tumors had moderate-to-high GR expression.
In patients lacking AR resistance markers (n=8), those with moderate/high GR (n=6) had prolonged time on treatment vs low GR (n=2).
ORIC-114 showed superior brain penetration and tumor regressions in HER2+ breast cancer models; 90% CR in EGFR exon20 NSCLC xenograft.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.